CEBPA and fatty liver disease: In addition, quantitative PCR revealed a decrease upon Cpd17 treatment in inflammatory markers F4/80, CCL2 and intracellular cell adhesion molecule (iCAM1), HSC‐specific marker α‐SMA and liver steatosis marker CCAAT‐enhancer‐binding proteins (C/EBP) (Rahman et al, 2007) (Fig EV4).